{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"517"},{"groupId":"OG001","value":"428"}]}],"title":"0: Fit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"202"}]}],"title":"1: Intermediate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"130"}]}],"title":"≥2: Frail"},{"categories":[{"measurements":[{"groupId":"OG000","value":"836"},{"groupId":"OG001","value":"680"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1761"},{"groupId":"OG001","value":"1440"}],"units":"Participants"}],"description":"Frailty is defined as the combination of unintentional weight loss, exhaustion, low physical activity, slow walking speed, and muscular weakness. The Myeloma Frailty Index is a composite index that was calculated using the points system, which produces a range of values from 0 to 5. Participants with score 0= fit, score 1= intermediate, and score ≥2= frail. Higher score indicates likeliness that the predicted outcome will result in frailty. The line of Therapy was determined at study entry.","groups":[{"description":"The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG000","title":"1st Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG001","title":"2nd Line of Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Enrolled Population included all participants who signed the inform consent form. Overall number of participants analyzed is the number of participants available for analysis.","reportingStatus":"POSTED","timeFrame":"At Baseline","title":"Number of Participants With Myeloma Frailty Index","type":"PRIMARY","unitOfMeasure":"Participants"}